Trial Profile
Relative Bioavailability of BI 207127 FF Tablets, BI 207127 FF Modified Tablets and BI 207127 TFII Tablets Administered Orally as Three Tablets (Single Dose) to Healthy Male Volunteers, an Open-label, Randomised Three-way Crossover Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs Deleobuvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- 04 Apr 2012 Actual patient number (18) added as reported by ClinicalTrials.gov.
- 04 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2012 Planned End Date changed from 1 May 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.